Skip to main content
. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432

Fig 4. Survival after diagnosis with MBC according to clinical trial enrollment stratified by biologic subtype: (a) HR+, (b) HER2+, and (c) TNBC.

Fig 4